AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04762719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PET/CT Scan with 11C-ER176
Description: Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
Study NCT04762719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Core biopsy of gastric muscle
Description: The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
Study NCT04927624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block
Description: The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
Study NCT04927624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quoadratus lumborum block
Description: quoadratus lumborum block
Study NCT06421558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neubie Direct Current Electrical Stimulation Device
Description: Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
Study NCT06421558 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Stimulation
Description: Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
Study NCT05367089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months.
Study NCT05367089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-Mesitran
Description: Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months.
Study NCT05031351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withania somnifera
Description: Nuclear Factor Kappa Beta Inhibitor
Study NCT05031351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT05883111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV DNA methylation assay
Description: HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
Study NCT05883111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV DNA methylation assay
Description: HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
Study NCT06266013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
Study NCT06266013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
Study NCT05018780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique.
Study NCT05018780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacral Manipulation
Description: * To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation.
Study NCT06516471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventinal Navigation System Group
Description: The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
Study NCT06516471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventinal Navigation System Group
Description: The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
Study NCT05321537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: A somatosensory training and an endurance-strength training protocol
Study NCT05953415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
Study NCT05953415 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
Study NCT06228339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets
Description: Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
Study NCT06228339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets
Description: Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
Study NCT06228339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (Reference Drug)
Study NCT06228339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (Reference Drug)
Study NCT05001620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
Study NCT06425016 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Description: Bariatric Surgery
Study NCT06425016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Sleeve Gastrectomy (RSG)
Description: Bariatric Surgery
Study NCT05531955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Oral Capsule
Description: pirfenidone capsules were added to patients receiving basic treatment
Study NCT05531955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo oral capsules were added to patients receiving basic treatment
Study NCT05529433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART)
Description: Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
Study NCT05529433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smart Burs
Description: Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
Study NCT05529433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemo-Mechanical Caries Removal (CMCR)
Description: Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
Study NCT04808037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
Study NCT04807413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
Study NCT04807413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care treatment
Description: standard of care treatment
Study NCT05106478 — intervention group
Intervention type: DEVICE
Intervention: AuraGain
Description: Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
Study NCT05141253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD133
Description: The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
Study NCT06192732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A more plant-based diet during weight loss
Description: Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
Study NCT06135714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic therapy for 12 weeks after primary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study NCT06135714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy for 12 weeks after primary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study NCT06135714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy (SBRT/conventional RT)
Description: Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
Study NCT06135714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for the oligometastases
Study NCT06135714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Same systemic therapy after secondary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study NCT06135714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Same systemic therapy after secondary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study NCT05397652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
Study NCT05397652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
Study NCT05136638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTi
Description: The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
Study NCT05136638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual coaching
Description: A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
Study NCT05136638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-therapist coaching
Description: A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
Study NCT05136638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist coaching
Description: A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
Study NCT05136638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene and Self-Monitoring Control
Description: An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
Study NCT05488431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Description: Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in >4300 individuals and is currently being studied in >14,000 individuals in CLEAR Outcomes (NCT02993406).
Study NCT05488431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05595226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RT3D-TEE-guided mitral valve repair
Description: RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
Study NCT05744843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: cardiovascular and lower limb strengthening exercise programme
Study NCT05744843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep venous stenting
Description: Planned surgical intervention
Study NCT05655871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transtheoretic Model Based Video Exercise Training
Description: Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
Study NCT05655871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Maintenance Practice
Description: Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
Study NCT04729517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI201901
Description: Twice daily inhaled AI201901 for 4 weeks
Study NCT04729517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride
Description: Twice daily inhaled Azelastine Hydrochloride for 4 weeks